Exhibitor Product Theaters

In-Person Exhibitor Product Theater

Open to all in-person ACG 2025 attendees. These presentations provide additional educational opportunities for attendees. No CME is provided for Theater presentations.

The Exhibitor Product Theater is located in Booth 345 in the Exhibit Hall.

Sunday, October 26

A discussion on the role of an IL-23 in the management of Crohn’s disease and ulcerative colitis

Remo Panaccione, MD
5:20 pm - 6:00 pm

A discussion on the role of an IL-23 in the management of Crohn’s disease and ulcerative colitis. Join Dr. Remo Panaccione on Sunday, October 26 at 5:20 pm for a presentation sponsored by AbbVie. Dr. Panaccione will review clinical outcomes of the first IL-23 inhibitor for Crohn’s disease and ulcerative colitis.

This program is sponsored by AbbVie.

Discover VELSIPITY^® (etrasimod): An Rx tablet treatment option from Pfizer

Anita Afzali, MD, MPH, MHCM, FACG
6:15 pm – 7:00 pm

Don’t miss an exciting presentation from an expert about a prescription tablet from Pfizer. Join us for an overview of key efficacy and safety data, steps in getting patients started, and other clinical treatment considerations. PP-V1A-USA-0953.

This program is sponsored by Pfizer Inc.

Monday, October 27

Empowering Care for Adult Patients With IBS-C

TBD
10:30 am – 11:15 am

Constipation and abdominal symptoms are the hallmark symptoms of irritable bowel syndrome with constipation (IBS-C), a chronic and burdensome condition. Come to a clinical review to learn more about management of IBS-C in adults.

This program is sponsored by AbbVie & Ironwood.

Explore the MOA and robust clinical profile of a biologic for UC and Crohn’s

Stephen B. Hanauer, MD, MACG
11:30 am – 12:00 noon

What makes a biologic different? Learn about a treatment for moderate to severe UC and Crohn’s that offers a combination of characteristics that may make it the right choice for your patients as their first biologic. Join us and find out what they are.

This program is sponsored by Takeda Pharmaceuticals U.S.A., Inc.

Clinical Deep Dive: Unlocking the treatment potential of Rezdiffra

Ashwini P. Mehta, DO and Christian L. Horn, MD
12:15 pm – 12:45 pm

Please join us for an engaging and highly anticipated educational panel presentation focusing on Rezdiffra, including the clinical data and patient cases.

This program is sponsored by Madrigal Pharmaceuticals.

Striving for Durable Outcomes in Crohn’s

Miguel Regueiro, MD, FACG
1:00 pm – 1:30 pm

Striving for Durable Outcomes in Crohn’s: Join Dr. Miguel Regueiro on Monday, October 27 at 1:00 pm for a presentation sponsored by AbbVie. Dr. Regueiro will explore a therapy that helps achieve powerful clinical and endoscopic outcomes for adult TNFi-IR patients with moderate to severe Crohn’s disease.

This program is sponsored by AbbVie.

Eosinophilic Esophagitis (EoE): Who’s in Your Waiting Room?

Paul Feuerstadt, MD, FACG
1:45 pm – 2:15 pm

EoE symptoms are often nonspecific, leading to delayed diagnosis and disease progression. Could you be missing these patients? Today, we'll explore a case and a treatment option for your appropriate patients. Someone like this patient could be sitting in your waiting room.

This program is sponsored by Sanofi and Regeneron.

Integrating a Different Mechanism of Action, a Different class of therapy, Into the treatment of Adults with IBS-C

Bryan Curtin, MD, MHSc
2:30 pm – 3:00 pm

Please join us for an engaging discussion led by Bryan Curtin, MD, MHSc, as he shares important clinical considerations in managing adult patients with IBS-C. The presentation will include interactive patient case studies, along with efficacy and safety data from two phase three clinical trials.

This program is sponsored by Ardelyx.

Expert Insights on GERD Therapy: A Case-Based Approach With a First-in-Class Acid Suppressant

John E. Pandolfino, MD, MSCI, FACG
3:45 pm – 4:30 pm

Join Dr. John Pandolfino for an engaging session on therapeutic options for the treatment of GERD (gastroesophageal reflux disease) in adults.

This program is sponsored by Phathom Pharmaceuticals.

Tuesday, October 28

Hear the Latest: New Data on TREMFYA^® (guselkumab)

Bincy P. Abraham, MD, MS, FACG and Raymond K. Cross, MD, MS, FACG
10:35 am – 11:30 am

Join us as we share new data for TREMFYA^® in both UC and Crohn's disease.

This program is sponsored by Johnson & Johnson.

Risk stratification of patients with Barrett’s esophagus traditionally considered at low risk of progression to HGD/EAC

Emmanuel C. Gorospe, MD, MPH, FACG
11:45 am – 12:15 pm

Understanding that we haven’t been able to reduce death from esophageal cancer: insights into identifying patients traditionally considered low risk.

This program is sponsored by Castle Biosciences.

Strive Towards Treatment Goals

Stephen B. Hanauer, MD, MACG and George Salem, MD, FACG
12:30 pm – 1:00 pm

Discuss short-, intermediate-, and long-term treatment goals for adult patients with moderately to severely active ulcerative colitis or Crohn's disease. Also review bowel urgency data, long-term data, including efficacy regardless of biologic experience, and access and patient support services for a treatment option.

This program is sponsored by Eli Lilly and Company.

Eosinophilic Esophagitis: Clinical Implications of Disease Progression

Nirmala Gonsalves, MD, FACG
1:15 pm – 1:45 pm

EoE is a chronic and progressive disease of the esophagus, often overlooked or misdiagnosed. Join us to learn about how early recognition and comprehensive assessment – including monitoring of symptoms, histology, and endoscopic findings – is essential to help prevent complications and improve patient outcomes.

This program is sponsored by Sanofi and Regeneron.

Addressing MASH in Appropriate Patients: From Science to Clinical Practice

Rohit Looma, MD, MHSc
2:00 pm – 2:30 pm

Join us as we discuss the urgent need to identify patients with metabolic dysfunction-associated steatohepatitis (MASH) at risk for fibrosis progression, review the screening guidelines, and present clinical data on MASH management from a phase 3 study.

This program is sponsored by Novo Nordisk, Inc.

Understanding ZYMFENTRA: 2-year LIBERTY -CD and UC trials

Shadi Hamdeh, MD
2:45 pm – 3:15 pm

This product theater will provide a clinical overview of Zymfentra and its role in infliximab-based treatment strategies for patients with moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD). The session will cover key findings from the LIBERTY-CD and LIBERTY-UC registration trials, including long-term (2-year) data, as well as guidance on administration schedules and available patient support programs.

This program is sponsored by Celltrion, Inc.

The Pancreas, the Bile Duct, and Beyond: Exploring a New Treatment Option for IgG4-Related Disease

Parvez S. Mantry, MD
3:30 pm – 4:00 pm

This product theater will offer expert clinical insights into the diagnosis and management of IgG4-related disease (IgG4-RD), including gastrointestinal manifestations, type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis. The presentation will review the importance of assessing extra-GI involvement and the role of multidisciplinary comanagement. Additionally, the session will highlight key clinical trial data for the first and only approved treatment for IgG4-RD, emphasizing updates on the latest advances in IgG4-RD management.

This program is sponsored by Amgen.